This article is more than 5 years old. Information may no longer be current.
Second-line pazopanib effective in advanced RCC
Click Here to Manage Email Alerts
Pazopanib demonstrated activity as a second-line treatment in patients with metastatic clear cell renal cell carcinoma who underwent first-line single-agent treatment with sunitinib or bevacizumab, according to results of a phase 2 trial.
More than 75% of the study population achieved disease control with pazopanib (Votrient, GlaxoSmithKline), an orally administered angiogenesis inhibitor.
The Sarah Cannon Oncology Research Consortium study included 55 patients with advanced renal cell carcinoma. Of them, 39 had previously received sunitinib (Sutent, Pfizer) and 16 had received bevacizumab (Avastin, Genentech).
All patients received 800 mg pazopanib daily for 8 weeks. Treatment continued until disease progression or high levels of toxicity.
Researchers used RECIST criteria to measure responses.
Median follow-up was 16.7 months.
Researchers reported an overall disease control rate of 76%. Fifteen patients (27%) demonstrated objective response and 27 (49%) achieved stable disease.
Median PFS was 7.5 months (95% CI, 5.4-9.4). PFS rates were similar between patients regardless of whether they received sunitinib or bevacizumab during first-line treatment.
The estimated 24-month OS rate for the entire cohort was 43%.
“Pazopanib is an active agent for the treatment of advanced clear cell renal carcinoma, even after failure of sunitinib or bevacizumab,” the researchers concluded. “Treatment with pazopanib should be considered early in the sequence of therapy for patients with advanced renal cell carcinoma.”
Disclosure: See the full study for a list of the researchers’ relevant financial disclosures.
Click Here to Manage Email Alerts